Ulcerative colitis (UC) is a chronic inflammatory disorder with a complex etiology, characterized by intestinal inflammation and barrier dysfunction. Platycodon grandiflorus polysaccharides (PGP), the primary component of Platycodon grandiflorus, and hesperidin (Hesp), a prominent active component in Citrus aurantium L. (CAL), have both demonstrated anti-inflammatory properties. This study aims to elucidate the underlying mechanism of the synergistic effect of PGP combined with Hesp on UC, focusing on the coordinated interaction between the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) and Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathways. A mouse model of UC induced by dextran sulfate sodium (DSS) and a cell model using lipopolysaccharide (LPS)-induced RAW264.7/IEC6 cells were employed to investigate the in vitro and in vivo anti-inflammatory effects of PGP combined with Hesp on UC and its potential mechanism of action. The results indicated that compared to the effects of either drug alone, the combination of PGP and Hesp significantly modulated inflammatory factor levels, inhibited oxidative stress, regulated colonic mucosal immunity, suppressed apoptosis, and restored intestinal barrier function in vitro and in vivo. Further in vitro studies revealed that PGP significantly inhibited the PI3K/AKT signaling pathway, while Hesp significantly inhibited the JAK2/STAT3 signaling pathway. The use of inhibitors and activators targeting both pathways validated the synergistic effects of PGP combined with Hesp on the PI3K/AKT and JAK2/STAT3 signaling pathways. These findings suggest that PGP combined with Hesp exhibits a synergistic effect on DSS-induced colitis, potentially mediated through the phosphatase and tensin homolog (PTEN)/PI3K/AKT and interleukin-6 (IL-6)/JAK2/STAT3 signaling pathways.
Animals ; STAT3 Transcription Factor/genetics* ; Janus Kinase 2/genetics* ; Polysaccharides/administration & dosage* ; Colitis, Ulcerative/chemically induced* ; Mice ; Signal Transduction/drug effects* ; Proto-Oncogene Proteins c-akt/genetics* ; Drug Synergism ; Male ; Hesperidin/administration & dosage* ; Platycodon/chemistry* ; Phosphatidylinositol 3-Kinases/genetics* ; Disease Models, Animal ; RAW 264.7 Cells ; Mice, Inbred C57BL

Objective:To investigate the dignity status of lymphoma patients during perichemotherapy, and to analyze the influencing factors.Methods:The convenience sampling method was used to investigate 230 lymphoma patients during perichemotherapy in Affiliated Tumor Hospital of Xinjiang Medical University from August 2020 to February 2021 by using general data questionnaire and patient dignity scale. Dual logistic regression was used to analyze the influencing factors of dignity.Results:The dignity score of patients with malignant lymphoma during perichemotherapy was 42.1±16.8, and 30.0% (69/230) patients had obvious dignity impairment. Among 5 dimensions of patient dignity, the scores of physical and mental pain, self-cognition, social role function independence and social support were 1.8±0.8, 1.8±0.9, 1.7±0.9, 1.6±0.7 and 1.2±0.5, respectively. Each patient had an average of 4.1 dignity problems, and five items with the highest score were worrying about their future (physical and mental pain dimension) [(2.1±1.1) scores, 50.4% (116/230)], feeling uncomfortable (physical and mental pain dimension) [(2.0±1.1) scores, 56.5% (130/230)], feeling a burden to others (self-perception dimension) [(2.0±1.1) scores, 33.5% (77/230)], feeling depressed (physical and mental pain dimension) [(1.9±1.0) scores, 53.5% (123/230)], feeling like a different person (self-perception dimension) [(1.9±1.1) scores, 49.1% (113/230)]. Logistic regression analysis showed that widowed (compared with unmarried: OR = 2.108, 95% CI 1.562-3.570), barely affordable and difficult to afford (compared with fully affordable: OR = 2.163, 4.307, respectively; 95% CI 1.120-7.469, 1.374-12.807), disease acceptance and negative (compared with positive: OR = 2.003, 3.694, respectively; 95% CI 1.358-6.599, 1.221-9.061), Eastern Cooperative Oncology Group (ECOG) score 2-4 (compared with score 0: OR = 3.753, 4.720, 5.044, respectively; 95% CI 1.352-9.506, 1.514-12.793, 2.221-15.539), patients with B symptom (compared with those without B symptom: OR = 1.962, 95% CI 1.100-3.501), patients with severe chemotherapy reaction (compared with those without severe chemotherapy reaction: OR = 4.814, 95% CI 2.714-8.539) were independent risk factors for obvious dignity loss of patients during perichemotherapy (all P < 0.05), and married was an independent protective factor compared with unmarried ( OR = 0.192, 95% CI 0.036-0.807, P < 0.05). Conclusion:Patients with lymphoma have impaired dignity during perichemotherapy. Medical staff should pay attention to the influencing factors of impaired dignity and develop targeted intervention programs to reduce the impaired dignity of patients.